Homoharringtonine (HHT) plus cytarabine (Ara-C) for chronic myeloid leukemia in accelerated phase (CML-AP).

被引：0
|
作者：
Maloisel, F
De Sarrazin, A
Fohrer, C
Rousselot, P
Maisonneuve, H
Lucas, P
Campos, F
Dufour, P
Bergerat, JP
机构：
[1] Hop Civil, Dept Hematol & Oncol, Strasbourg, France
[2] Hop St Louis, Paris, France
[3] CHD, La Roche Sur Yon, France
[4] Polyclin Les Bleuets, Reims, France
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4778
引用
收藏
页码：262B / 262B
页数：1
相关论文
共 50 条
  • [1] Homoharringtonine (HHT) and low-dose cytarabine (ara-C) in patients with late chronic phase (CP) chronic myelogenous leukemia (CML).
    OBrien, S
    Kantarjian, H
    Keating, M
    Beran, M
    Rios, M
    Robinson, J
    Kornblau, S
    Talpaz, M
    BLOOD, 1997, 90 (10) : 2306 - 2306
  • [2] Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML)
    Maiti, Abhishek
    Kantarjian, Hagop M.
    Ferrajoli, Alessandra
    Estrov, Zeev
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Jabbour, Elias J.
    Ravandi, Farhad
    O'Brien, Susan M.
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [3] Imatinib (I) plus etoposide (Vp16) compared to I plus cytarabine (Ara-C) for the frontline treatment of accelerated phase (AP) chronic myeloid leukemia (CML)
    Cervera, E.
    Vargas, P.
    Cruz, J.
    Enriquez, V.
    Martinez, A.
    Lozano, V.
    Candelaria, M.
    Labardini, J.
    Hurtado, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Homoharringtonine (HHT) for chronic myeloid leukemia in accelerated phase (CML AP): A follow-up study.
    Al-Beirouti, BM
    Chen, C
    Yee, K
    Kamel-Reid, S
    Keating, A
    BLOOD, 2001, 98 (11) : 254B - 255B
  • [5] Imatinib (I) compared to I plus cytarabine (Ara-C) for the frontline treatment of chronic phase (CP) chronic myeloid leukemia (CML)
    Hurtado-Monroy, R.
    Vargas, P.
    Martinez, A.
    Cruz, J.
    Enriquez, V.
    Gutierrez, O.
    Candelaria, M.
    Aguayo, A.
    Cervera, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP)
    Ohanian, Maro
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    Jabbour, Elias J.
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Ferrajoli, Alessandra
    Kadia, Tapan M.
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [7] Safety and tolerability of STI-571 in patients with Ph plus chronic myeloid leukemia in accelerated phase (CML-AP) previously autotransplanted
    Boqué, C
    Encuentra, M
    Peralta, T
    Sala, O
    Moreno, C
    Petit, J
    Sarrà, J
    Grañena, A
    BONE MARROW TRANSPLANTATION, 2002, 29 : S35 - S35
  • [8] Retrospective comparison of imatinib versus interferon plus cytarabine (IFN/Ara-c) for chronic myelogenous leukemia (CML) patients in chronic phase (CP).
    Guilhot, F
    Roy, L
    Guilhot, J
    Krahnke, T
    Guerci, A
    Druker, B
    Larson, R
    O'Brien, S
    So, C
    Massimini, G
    BLOOD, 2005, 106 (11) : 52A - 52A
  • [9] Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP)
    Ohanian, Maro
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    O'Brien, Susan
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Burton, Elizabeth M.
    Trinh, Long Xuan
    Ferrajoli, Alessandra
    Jabbour, Elias
    Kadia, Tapan
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1614 - 1615
  • [10] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Richard L Momparler
    Experimental Hematology & Oncology, 2 (1)
12345